WO2005082283A1 - Medical devices - Google Patents

Medical devices

Info

Publication number
WO2005082283A1
WO2005082283A1 PCT/US2005/005630 US2005005630W WO2005082283A1 WO 2005082283 A1 WO2005082283 A1 WO 2005082283A1 US 2005005630 W US2005005630 W US 2005005630W WO 2005082283 A1 WO2005082283 A1 WO 2005082283A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
stent
sugar
therapeutic agent
medical
medical stent
Prior art date
Application number
PCT/US2005/005630
Other languages
French (fr)
Inventor
Fredericus A. Colen
David Knapp
Original Assignee
Boston Scientific Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00389The prosthesis being coated or covered with a particular material
    • A61F2310/0097Coating or prosthesis-covering structure made of pharmaceutical products, e.g. antibiotics

Abstract

In some embodiments , medical devices, such as stents, can be suitable for drug delivery and can include a layer (24) of sugar, sugar derivative, inorganic ionic salt, polysaccharide, amino acid, amino acid derivative, polypeptide, surfactant, or combination thereof.

Description

Medical Devices

TECHNICAL FIELD This invention relates to medical devices, particularly endoprostheses.

BACKGROUND The body includes various passageways such as arteries, other blood vessels, and other body lumens. For various treatments and diagnostic techniques, it is often desirable to deliver a medical device into these lumens. For example, these passageways sometimes become occluded or weakened. The passageways can be occluded by e.g. a tumor, restricted by plaque, or weakened by an aneurysm. When this occurs, the passageway can be reopened or reinforced, or even replaced, with a medical endoprosthesis. An endoprosthesis is typically a tubular member that is placed in a lumen in the body. Examples of endoprostheses include stents and covered stents, sometimes called "stent-grafts". An endoprosthesis can be delivered inside the body by a catheter that supports the endoprosthesis in a compacted or reduced-size form as the endoprosthesis is transported to a desired site. Upon reaching the site, the endoprosthesis is expanded, for example, so that it can contact the walls of the lumen. The expansion mechanism may include forcing the endoprosthesis to expand radially. For example, the expansion mechanism can include the catheter carrying a balloon, which carries the endoprosthesis. The balloon can be' inflated to deform and to fix the expanded endoprosthesis at a predetermined position in contact with the lumen wall. The balloon can then be deflated, and the catheter removed. In another delivery technique, the endoprosthesis is self-expanding. For example, the endoprosthesis can be formed of an elastic material that can be reversibly compacted and expanded. During introduction into the body, the endoprosthesis is restrained in a compacted condition. Upon reaching the desired implantation site, the restraint is removed, for example, by retracting a restraining device such as an outer sheath, enabling the endoprosthesis to self-expand by its own internal elastic restoring force. Another self-expansion teclmique uses shape memory metals which can "remember" a particular geometric configuration, e.g. an expanded condition, upon exposure to a trigger, such as an increase in temperature. The endoprosthesis can carry a drug, such as an antiproliferative, to reduce the likelihood of restenosis, i.e., reclosure of the vessel due to immune reactions by the body at the treatment site.

SUMMARY hi one aspect, the invention features a medical stent with a generally tubular body. The medical stent also includes a therapeutic agent, and a sugar, sugar derivative, or inorganic ionic salt. In another aspect, the invention features a stent delivery system that includes a catheter with a balloon and a medical stent device, and that has a generally tubular body, a therapeutic agent, and a sugar, sugar derivative, or inorganic ionic salt. In another aspect, the invention features a stent delivery system that includes a catheter with a retractable sheath and a medical stent device, and that has a generally tubular body, a therapeutic agent, and a sugar, sugar derivative, or inorganic ionic salt. In another aspect, the invention features a medical stent with a generally tubular body and a sugar, sugar derivative, or inorganic ionic salt. In another aspect, the invention features a method of making a coated stent, the method including providing a stent, providing a therapeutic agent, and coating the stent with a layer of sugar, sugar derivative, or inorganic ionic salt. h various aspects, the invention includes an implantable medical device (e.g., a stent) that includes an implantable body, a therapeutic agent and a sugar, sugar derivative, inorganic ionic salt, surfactant, polysaccharide, polypeptide, amino acid, amino acid derivative, or a combination thereof. Embodiments can include one or more of the following features. The sugar, sugar derivative, or salt can have a solubility of at least 0.14 gram/mL of water, and/or a melting point of about 47°C or more. The stent can include a sugar or a sugar derivative (e.g., sucrose, sorbose, glucosamine, mannitol). The stent can include an inorganic ionic salt (e.g., sodium chloride, potassium chloride, sodium carbonate). The stent can have a layer that includes a therapeutic agent and the sugar, sugar derivative, or salt. The stent can have a layer of sugar, sugar derivative, or salt that covers a therapeutic agent-containing reservoir. The reservoir can be a layer of therapeutic agent. The reservoir can define pores in which the therapeutic agent can be disposed. The reservoir can include metal that is integral with the stent body. The stent can further include a second therapeutic agent that is carried by the layer, and the second therapeutic agent can be different from the therapeutic agent that is carried by the reservoir. The therapeutic agent can be an antithrombogenic, an antioxidant, an anti- inflammatory, an antiproliferative, and/or an antibiotic. The stent can be a self-expanding stent or a balloon-expandable stent. The stent can be a vascular stent. Coating can include dip coating and/or spray coating. Coating can include forming a preform layer and fixing the preform layer to the stent. The perform layer can be fixed by applying a solution of, or a liquid form of, a sugar, sugar derivative, or to the stent. Embodiments of the invention can have one or more of the following advantages. The protective layer can prevent the therapeutic agent from being exposed to or released into the body until it has reached its target site. The layer is highly bioerodible and water-soluble, such that it rapidly dissolves when the treatment site is reached. The layer can be flexible, such that it can be moved through a tortuous lumen and expanded as the strut expands without significant fracture, flaking, or disruption. Furthermore, the protective layer is the same as, or chemically analogous to, substances that are either commonly present in the body, or that the body regards as non-foreign. As a result, the protective layer generally is not of a material type that elicits an adverse reaction by the body, such as inflammation or an autoimmune response. The layer material typically is easily metabolized. In addition, the protective layer does not adversely interact with the drug during storage or during delivery. The layer can be relatively inexpensive and readily commercially available. Still further aspects, features, and advantages follow.

DESCRIPTION OF DRAWINGS FIGS. 1A and IB are perspective views of a stent in the compressed and expanded condition, respectively. FIG. 2 is a greatly enlarged cross-section through the side wall of a stent. FIG. 3 is a greatly enlarged cross-section through a side wall of a stent. FIGS. 4A-4C are a schematic representation of a stent delivery. FIGS. 5A-5C are another schematic representation of a stent delivery. DETAILED DESCRIPTION Referring to FIGS. 1A and IB, a stent 10 includes a generally tubular body 12. The tubular body includes aperture regions 14 provided in a pattern to facilitate stent functions, such as radial expansion and lateral flexibility. Referring particularly to FIG. 1 A, for delivery into the body, the stent 10 is provided or maintained in a relatively small diameter condition corresponding to a diameter Dc. Referring to FIG. IB, upon delivery to the treatment site, the stent 10 is expanded to a larger diameter, Dex , so that the stent is in contact with the lumen wall. The stent may be expanded by a mechanical expander, such as an inflatable balloon, or it may be self-expanding. The body of the stent may be fomied by a generally continuous sheet or by filaments that are wrapped, braided, knitted or otherwise configured to generally define a stent.

The stent is delivered into the body on a catheter, such as a balloon catheter. The catheter can include a retractable sheath that concentrically surrounds the stent during delivery and is retracted during employment at the treatment site. Alternatively, the stent may be exposed to the body lumen during delivery. A suitable stent design is the Express stent, available from Boston Scientific, Natick, Mass. Balloon expandable and self-expanding stents and delivery systems are further discussed in Heath, U.S. 5,725,570, the entire contents of which are incorporated herein by reference. Referring now to FIG. 2, a cross-section through the stent side wall, the stent 10 includes a body 20 onto which are provided a drug reservoir 22 and a protective layer 24. The body 20 is formed of material capable of performing the expansion function of the stent. For example, the body 20 may be a highly elastic metal, in the case of a self-expanding stent, or a plastically deformable metal, in the case of a balloon-expandable stent. The drug reservoir 22 contains a therapeutic agent to be released in the body during use of the stent. The protective layer 24 covers the drug reservoir prior to and, if desirable, during the delivery and implantation of the stent into the body. For example, the protective layer protects the reservoir from abrasion during packaging, shipping, unpacking, and delivery. The protective layer can be removed prior to delivery into the body. Alternatively, the protective layer can also protect the reservoir from premature exposure to body fluid during delivery. The protective layer can be made of a sugar, a sugar derivative, a simple inorganic ionic salt, or a combination thereof. These material(s) are chemically the same as, or analogous to, substances that are commonly present in the body and material types that typically do not cause adverse reactions, such as inflammation, or that do not interact adversely with the drug or reservoir. The protective layer preferably erodes at a relatively rapid rate, so that the therapeutic agent can be released into the body at the appropriate time, i.e., when the endoprosthesis reaches the target site. Preferably, the protective layer will dissolve within about 10 to 30 minutes after contact with bodily fluids. The protective layer preferably has a solubility of at least about 0.14 gram/mL of water at about 25°C (unless otherwise noted, all of the following solubility values are at about room temperature, i.e., about 25°C). Additionally, the protective layer preferably is flexible, such that it can be maneuvered within the lumen relatively easily. The protective layer preferably is a material that is relatively robust to abrasion, so that it can withstand friction created by contact with the lumen wall or the sheath of the catheter, for example. The protective layer maintains its structural integrity while it is passing through the body; i.e., the protective layer should not undergo substantial plastic or elastic deformation as it is dissolving. Deformation can be minimized by selecting protective layer materials with melting points substantially above, e.g. about 10°C or 50°C or more, nonnal body temperature (about 37°C). Suitable sugars are carbohydrates composed of polyhydroxy aldehydes and ketones and their derivatives. Examples of suitable sugars include sucrose (Cι2H22Oπ), dextrose (C62O6), and sorbose (C62O6). Sucrose has a solubility of about 2 grams/mL of water and a melting point of about 185-186°C. Dextrose has a solubility of about 1 gram/mL of water and a melting point of about 146-150°C. Sorbose is freely soluble in water and has a melting point of about 162-165°C. Suitable sugar derivatives include sugar alcohols, such as polyhydric alcohols having no more than one hydroxy group attached to each carbon atom, formed by the reduction of the carbonyl group of a sugar to a hydroxyl group. A suitable sugar alcohol is mannitol (C64O6). Mannitol has a solubility of about 0.18 gram/mL of water and a melting point of about 168°C. Another example of a sugar derivative is glucosamine (C63NO5), an amino derivative of glucose. Suitable inorganic ionic salts include salts containing a cation and an anion, where the cation is an alkali or alkaline earth metal, and the anion is a halide or a polyatomic ion. Examples of suitable salts include sodium chloride (NaCl), potassium chloride (KC1), and sodium carbonate (Na2CO3). Sodium chloride has a solubility of about 0.36 gram/mL of water and a melting point of about 804°C. Potassium chloride has a solubility of about 0.36 gram/mL of water and a melting point of about 773°C. In embodiments, the protective layer can be made of a polysaccharide (e.g., starch, dextran, cyclodextrin), an amino acid, an amino acid derivative, a polypeptide, a surfactant (e.g., phosphatidylcholine, a Tween® surfactant, or a lipid), or a combination thereof. The thickness of the protective layer can be selected on the basis of the protective layer's solubility and the desired dissolution time of the protective layer. Protective layers that are highly soluble can be thicker than those protective layers that are more insoluble. In embodiments, the protective layer has a thickness of from about 0.1 micron to about 20 microns. i embodiments, the protective layer dissolves en route to the target site or it may dissolve once the stent has reached the target site, h some cases, the protective layer partially dissolves en route to the target site, and finishes dissolution once the stent has reached the target site. The protective layer can be applied to the stent by techniques including spraying and dip coating. The protective layer can also be preformed, e.g. by casting. The preformed protective layer can be applied to the stent by an adhesive layer, e.g. the molten or solubilized material of the protective layer itself (in the case of mannitol), or a heated syrup of fructose and sucrose which solidifies upon cooling, or syrups of other sugars or sugar derivatives (such as mannitol or sorbitol). The drug reservoir can take several different forms. For example, the drug layer can be a layer of the drug itself, solidified on the surface of the stent. Alternatively or additionally, the drug can be contained in a reservoir defined by a different material, e.g. a polymer, that is also bioerodible and/or functions as a time-release membrane. For example, the reservoir can be formed of the materials suitable for the protective layer discussed above. A drug reservoir can be formed by a stent body that has an integral porous surface. The porous surface can be formed by machining, laser drilling, sintering or anodization. Sintering is a process by which metal particles are bonded together without being entirely melted. Rather, the particles are pressed together or molded into a certain shape via pressure. Then, the particles are heated to a point just below their melting point. The particles do not melt per se; instead, the particles bond together at their surfaces. The result is that spaces (i.e., "pores") remain between the bonded particles. Anodization is an electrolytic oxidation of a metal. For certain metals, such as aluminum, anodization creates a morphology of post-shaped elements on the surface of the metal, which can enhance strength. As a result, a porous structure can be formed generally without sacrificing the strength of the metal or impeding the function of the medical device. Referring to FIG. 3, greatly enlarged cross-section through a side wall of a stent, the stent side wall is composed of a base material 21, an intermediate layer 23, and a porous layer 26. The morphology of porous layer 26, which is formed by anodization, is a generally regular array of hollow post-shaped elements 30 defining internal volumes 27. Void regions 32 are defined between hollow post-shaped elements 30. A therapeutic agent 34 fills internal volumes 27 and void regions 32. A protective layer 36 covers porous layer 26 in order to prevent therapeutic agent 34 from being dispersed into the body before the stent has reached the target site. Anodization can be carried out directly on the stent body or a coating of a suitable anodizeable metal can be provided over the stent body. Anodization and stents with anodized surfaces are described, for example, in U.S. Patent Application No. 10/664,679, filed September 16, 2003, and entitled "Medical Devices", the entire contents of which are incorporated by reference herein. The term "therapeutic agent" includes one or more "therapeutic agents" or "drugs". The terms "therapeutic agents" and "drugs" are used interchangeably and include phannaceutically active compounds, nucleic acids with and without carrier vectors such as lipids, compacting agents (such as histones), virus (such as adenovirus, adeno-associated virus, retrovirus, lentivirus and a-virus), polymers, antibiotics, hyaluronic acid, gene therapies, proteins, cells, stem cells and the like, or combinations thereof, with or without targeting sequences. Specific examples of therapeutic agents include, for example, pharmaceutically active compounds, proteins, cells, stem cells, oligonucleotides, ribozymes, antisense oligonucleotides, DNA compacting agents, gene/vector systems (i.e., any vehicle that allows for the uptake and expression of nucleic acids), nucleic acids (including, for example, recombinant nucleic acids; naked DNA, cDNA, RNA; genomic DNA, cDNA or RNA in a noninfectious vector or in a viral vector and which further may have attached peptide targeting sequences; antisense nucleic acid (RNA or DNA); and DNA chimeras which include gene sequences and encoding for ferry proteins such as membrane translocating sequences ("MTS") and herpes simplex virus- 1 ("VP22")), and viral, liposomes and cationic and anionic polymers and neutral polymers that are selected from a number of types depending on the desired application. Non-limiting examples of virus vectors or vectors derived from viral sources include adenoviral vectors, herpes simplex vectors, papilloma vectors, adeno- associated vectors, retro viral vectors, and the like. Non-limiting examples of biologically active solutes include anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, and PPACK (dextrophenylalanine proline arginine chloromethylketone); antioxidants such as probucol and retinoic acid; angiogenic and anti-angiogenic agents and factors; agents blocking smooth muscle cell proliferation such as rapamycin, angiopeptin, and monoclonal antibodies capable of blocking smooth muscle cell proliferation; anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, acetyl salicylic acid, and mesalamine; calcium entry blockers such as verapamil, diltiazem and nifedipine; antineoplastic/antiproliferative/anti-mitotic agents such as paclitaxel, 5-fluorouracil, methotrexate, doxorubicin, daunorubicin, cyclosporine, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors; antimicrobials such as triclosan, dephalosporins, aminoglycosides, and nitorfurantoin; anesthetic agents such as lidocaine, buplvacaine, and ropivacaine; nitrix oxide (NO) donors such as lisidomine, molsidomine, L-argine, NO-protein adducts, NO-carbohydrate adducts, polymeric or oligomeric NO adducts; anti-coagulants such as D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide- containing compound, heparine, antithrombin compounds, platelet receptor antagonists, anti- tlirombin antibodies, anti-platelet receptor antibodies, enoxaparin, hirudin, Warafin sodium, Dicumarol, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet factors; vascular cell growth promoters such as growth factors, growth factor receptor antagonists, transcriptional activators, and translational promoters; vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilating agents; agents which interfere with endogenous vascoactive mechanisms; survival genes which protect against cell death, such as anti-apoptotic Bcl-2 family factors and Aid kinase; and combinations thereof. Cells can be of human origin (autologous or allogenic) or from an animal source (xenogeneic), genetically engineered if desired to deliver proteins of interest at the injection site. The delivery mediated is formulated as needed to maintain cell function and viability. In some cases, the protective layer may contain a drug, which may be the same as or different from the drug in the reservoir. For example, the protective layer may include one type of drug, e.g. an antithrombogenic agent which is released quickly during delivery and deployment, while the reservoir may contain a different type of drug, e.g. an anti-inflammatory which is released more slowly at the site. As discussed above, the stent body may be made out of any of a number of different materials. Referring to FIGS. 4A-4C, the delivery of a self-expanding stent is illustrated. The stent 10 is deployed on a catheter 38 and covered by a sheath 40. When the target site is reached, the sheath is retracted and the stent self-expands into contact with the body lumen. Referring now to FIGS. 5A-5C, the delivery of a balloon-expandable stent is illustrated. The stent 10 is carried on a catheter 42 over a balloon 44. When the treatment site is reached, the balloon is expanded to expand the stent into contact with the lumen wall. The stent body may be made of, for example, Nitinol, a nickel-titanium alloy that can provide stent with superelasticity and shape memory properties. In some cases, the stent body may be made of stainless steel (e.g., 300 series stainless steel), or aluminum. The stent body may be made of composite materials as described in Heath, U.S. 5,725,570, and Mayer, U.S. 5,800,511. A stent as described above has many different possible applications. For example, the stent may be used in the vascular system (e.g., in the coronary arteries), or in the gastrointestinal tract. The stent may be an esophageal stent. The stent may be used in the biliary duct, or in other body lumens. While a stent has been described above, a protective layer and a drug-containing reservoir may be applied to other implantable medical devices, and particularly to implantable medical devices that are suitable for drug delivery. For example, they may be used in guidewires, catheters (including balloon angioplasty catheters), or filters (including vena cava filters). Still other embodiments are possible. For example, where the protective layer material itself has a desirable therapeutic effect, e.g. if delivery of a sugar or salt to a treatment site is desired, the protective layer material can be applied to a stent that does not include a drug reservoir. All publications, applications, references, and patents referred to above are incorporated by reference in their entirety. Other embodiments are within the following claims.

Claims

WHAT IS CLAIMED IS:
1. A medical stent, comprising: a generally tubular body; a therapeutic agent; and a sugar, sugar derivative, or inorganic ionic salt.
2. The medical stent of claim 1 wherein the sugar, sugar derivative, or salt has a solubility of at least 0.14 gram/mL of water.
3. The medical stent of claim 1 wherein the sugar, sugar derivative, or salt has a melting point of about 47°C or more.
4. The medical stent of claim 1 wherein the stent comprises a sugar or sugar derivative.
5. The medical stent of claim 4 wherein the sugar or sugar derivative comprises sucrose, sorbose, glucosamine, or mannitol.
6. The medical stent of claim 1 wherein the stent includes an inorganic ionic salt.
7. The medical stent of claim 6 wherein the salt comprises sodium chloride, potassium chloride, or sodium carbonate.
8. The medical stent of claim 1 including a layer including a therapeutic agent and said sugar, sugar derivative, or salt.
9. The medical stent of claim 1 including a layer of sugar, sugar derivative, or salt that covers a therapeutic agent-containing reservoir.
10. The medical stent of claim 9 wherein the reservoir is a layer of therapeutic agent.
11. The medical stent of claim 9 wherein the reservoir defines pores and the therapeutic agent is disposed within the pores.
12. The medical stent of claim 9 wherein the reservoir comprises metal integral with the stent body.
13. The medical stent of claim 9 further comprising a second therapeutic agent, carried by the layer, wherein the second therapeutic agent is different from the therapeutic agent carried by the reservoir.
14. The medical stent of claim 1 wherein the therapeutic agent is selected from an antithrombogenic, antioxidant, anti-inflammatory, antiprohferative, or antibiotic.
15. The medical stent of claim 1 wherein the stent is a self-expanding stent.
16. The medical stent of claim 1 wherein the stent is a balloon-expandable stent.
17. The medical stent of claim 1 wherein the stent is a vascular stent.
18. A stent delivery system including a catheter with a balloon and a medical stent device, comprising: a generally tubular body; a therapeutic agent; and a sugar, sugar derivative, or inorganic ionic salt.
19. A stent delivery system including a catheter with a retractable sheath and a medical stent device, comprising: a generally tubular body; a therapeutic agent; and a sugar, sugar derivative, or inorganic ionic salt.
20. A medical stent comprising a generally tubular body and a sugar, sugar derivative or inorganic ionic salt.
21. The medical stent of claim 20 wherein the stent comprises a sugar or a sugar derivative.
22. The medical stent of claim 20 wherein the sugar or sugar derivative comprises sucrose, sorbose, glucosamine or mannitol.
23. The medical stent of claim 20 wherein the stent comprises an inorganic ionic salt.
24. The medical stent of claim 23 wherein the salt comprises sodium chloride, potassium chloride, or sodium carbonate.
25. A method of making a coated stent, comprising: providing a stent; providing a therapeutic agent; and coating the stent with a layer of sugar, sugar derivative, or inorganic ionic salt.
26. The method of claim 25 wherein coating comprises dip coating or spray coating.
27. The method of claim 25 wherein coating comprises forming a preform layer and fixing the preform layer to the stent.
28. The method of claim 27 wherein the perform layer is fixed by applying a solution of, or a liquid form of, a sugar, sugar derivative, or salt to the stent.
29. An implantable medical device, comprising: an implantable body; a therapeutic agent; and a sugar, sugar derivative, or inorganic ionic salt.
30. A medical stent, comprising: a generally tubular body; a therapeutic agent-containing reservoir; and a layer that covers the reservoir, the layer selected from the group consisting of sugars, sugar derivatives, inorganic ionic salts, surfactants, polysaccharides, polypeptides, amino acids, amino acid derivatives, and combinations thereof.
31. A medical stent, comprising: a generally tubular body; a therapeutic agent; and a surfactant.
PCT/US2005/005630 2004-02-26 2005-02-23 Medical devices WO2005082283A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10787618 US8137397B2 (en) 2004-02-26 2004-02-26 Medical devices
US10/787,618 2004-02-26

Publications (1)

Publication Number Publication Date
WO2005082283A1 true true WO2005082283A1 (en) 2005-09-09

Family

ID=34886815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/005630 WO2005082283A1 (en) 2004-02-26 2005-02-23 Medical devices

Country Status (2)

Country Link
US (1) US8137397B2 (en)
WO (1) WO2005082283A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US8066763B2 (en) 1998-04-11 2011-11-29 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
US8353949B2 (en) 2006-09-14 2013-01-15 Boston Scientific Scimed, Inc. Medical devices with drug-eluting coating
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8449901B2 (en) 2003-03-28 2013-05-28 Innovational Holdings, Llc Implantable medical device with beneficial agent concentration gradient
US8574615B2 (en) 2006-03-24 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7341598B2 (en) 1999-01-13 2008-03-11 Boston Scientific Scimed, Inc. Stent with protruding branch portion for bifurcated vessels
WO2003002243A3 (en) 2001-06-27 2004-03-04 Remon Medical Technologies Ltd Method and device for electrochemical formation of therapeutic species in vivo
WO2005122959A3 (en) 2004-06-08 2007-03-15 Advanced Stent Tech Inc Stent with protruding branch portion for bifurcated vessels
US8071155B2 (en) * 2005-05-05 2011-12-06 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US7778684B2 (en) * 2005-08-08 2010-08-17 Boston Scientific Scimed, Inc. MRI resonator system with stent implant
US20070112421A1 (en) * 2005-11-14 2007-05-17 O'brien Barry Medical device with a grooved surface
US7540881B2 (en) 2005-12-22 2009-06-02 Boston Scientific Scimed, Inc. Bifurcation stent pattern
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US20070244548A1 (en) * 2006-02-27 2007-10-18 Cook Incorporated Sugar-and drug-coated medical device
US20070208350A1 (en) * 2006-03-06 2007-09-06 Gunderson Richard C Implantable medical endoprosthesis delivery systems
US20070239256A1 (en) * 2006-03-22 2007-10-11 Jan Weber Medical devices having electrical circuits with multilayer regions
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
CA2659761A1 (en) 2006-08-02 2008-02-07 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
EP2959925A1 (en) 2006-09-15 2015-12-30 Boston Scientific Limited Medical devices and methods of making the same
US7955382B2 (en) 2006-09-15 2011-06-07 Boston Scientific Scimed, Inc. Endoprosthesis with adjustable surface features
CA2663212A1 (en) * 2006-09-15 2008-03-20 Boston Scientific Limited Magnetized bioerodible endoprosthesis
CA2663271A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Bioerodible endoprostheses and methods of making the same
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
ES2368125T3 (en) 2006-09-15 2011-11-14 Boston Scientific Scimed, Inc. bioerodible endoprostheses biostable inorganic layers.
CA2663762A1 (en) 2006-09-18 2008-03-27 Boston Scientific Limited Endoprostheses
US7951191B2 (en) 2006-10-10 2011-05-31 Boston Scientific Scimed, Inc. Bifurcated stent with entire circumferential petal
JP2010508909A (en) * 2006-11-03 2010-03-25 ボストン サイエンティフィック リミテッド Ion bombardment of the medical device
CA2668765A1 (en) * 2006-11-16 2008-05-29 Boston Scientific Limited Stent with differential timing of abluminal and luminal release of a therapeutic agent
US7842082B2 (en) 2006-11-16 2010-11-30 Boston Scientific Scimed, Inc. Bifurcated stent
DE602007010669D1 (en) 2006-12-28 2010-12-30 Boston Scient Ltd hear it
US9034456B2 (en) * 2006-12-28 2015-05-19 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US8070798B2 (en) * 2007-07-20 2011-12-06 Josiah Wilcox Drug eluting medical device and method
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US7883736B2 (en) * 2007-09-06 2011-02-08 Boston Scientific Scimed, Inc. Endoprostheses having porous claddings prepared using metal hydrides
US7959669B2 (en) 2007-09-12 2011-06-14 Boston Scientific Scimed, Inc. Bifurcated stent with open ended side branch support
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US20090076591A1 (en) * 2007-09-19 2009-03-19 Boston Scientific Scimed, Inc. Stent Design Allowing Extended Release of Drug and/or Enhanced Adhesion of Polymer to OD Surface
US7833266B2 (en) 2007-11-28 2010-11-16 Boston Scientific Scimed, Inc. Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment
US8277501B2 (en) 2007-12-21 2012-10-02 Boston Scientific Scimed, Inc. Bi-stable bifurcated stent petal geometry
DE102008008926A1 (en) * 2008-02-13 2009-08-20 Biotronik Vi Patent Ag A system for introducing an intraluminal endoprosthesis and method for fabricating such a system
JP2011512215A (en) * 2008-02-21 2011-04-21 エグザカトゥ Active ingredients or agents, in particular implantable medical device comprising a protective / holding layer for a water-soluble
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8932340B2 (en) 2008-05-29 2015-01-13 Boston Scientific Scimed, Inc. Bifurcated stent and delivery system
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
WO2009155328A3 (en) 2008-06-18 2010-09-16 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7951193B2 (en) 2008-07-23 2011-05-31 Boston Scientific Scimed, Inc. Drug-eluting stent
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US8920490B2 (en) 2010-05-13 2014-12-30 Boston Scientific Scimed, Inc. Endoprostheses
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
US9084692B2 (en) 2010-11-17 2015-07-21 Boston Scientific Scimed, Inc. Stent delivery system
US9220619B2 (en) 2010-11-17 2015-12-29 Boston Scientific Scimed, Inc. Stent delivery system
US8784468B2 (en) 2010-11-17 2014-07-22 Boston Scientific Scimed, Inc. Stent delivery systems and locking members for use with stent delivery systems
US9603728B2 (en) 2013-02-15 2017-03-28 Boston Scientific Scimed, Inc. Bioerodible magnesium alloy microstructures for endoprostheses
WO2015066181A1 (en) 2013-10-29 2015-05-07 Boston Scientific Scimed, Inc. Bioerodible magnesium alloy microstructures for endoprostheses

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071305A (en) * 1996-11-25 2000-06-06 Alza Corporation Directional drug delivery stent and method of use
WO2002047739A2 (en) * 2000-12-15 2002-06-20 Md3, Inc. Protective coating for stent
EP1260214A1 (en) * 1997-04-30 2002-11-27 Schneider (Usa) Inc., Drug-releasing coatings for medical devices
EP1273314A1 (en) * 2001-07-06 2003-01-08 Terumo Kabushiki Kaisha Stent
US6506437B1 (en) * 2000-10-17 2003-01-14 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device having depots formed in a surface thereof
WO2003035131A1 (en) * 2001-09-27 2003-05-01 Advanced Cardiovascular Systems, Inc. A rate-reducing membrane for release of an agent

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4334327A (en) * 1979-12-21 1982-06-15 University Of Utah Ureteral prosthesis
DK17885D0 (en) * 1985-01-14 1985-01-14 Karlsson Karl Anders antiviral
US4827940A (en) 1987-04-13 1989-05-09 Cardiac Pacemakers, Inc. Soluble covering for cardiac pacing electrode
US4950227A (en) * 1988-11-07 1990-08-21 Boston Scientific Corporation Stent delivery system
US5135516A (en) * 1989-12-15 1992-08-04 Boston Scientific Corporation Lubricious antithrombogenic catheters, guidewires and coatings
US5356381A (en) 1990-03-01 1994-10-18 Ensminger William D Implantable access devices
US5099060A (en) * 1990-06-12 1992-03-24 Rutgers, The State University Of New Jersey Synthesis of amino acid-derived bioerodible polymers
US5344411A (en) * 1991-02-27 1994-09-06 Leonard Bloom Method and device for inhibiting HIV, hepatitis B and other viruses and germs when using a catheter in a medical environment
USRE38653E1 (en) 1991-03-08 2004-11-16 Kabushikikaisha Igaki Iryo Sekkei Luminal stent, holding structure therefor and device for attaching luminal stent
US5500013A (en) * 1991-10-04 1996-03-19 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
WO1993006792A1 (en) * 1991-10-04 1993-04-15 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
JP2961287B2 (en) * 1991-10-18 1999-10-12 グンゼ株式会社 Biological conduit dilator, their preparation and stent
CA2079417C (en) * 1991-10-28 2003-01-07 Lilip Lau Expandable stents and method of making same
US5599352A (en) * 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
US7682647B2 (en) * 1999-09-03 2010-03-23 Advanced Cardiovascular Systems, Inc. Thermal treatment of a drug eluting implantable medical device
EP0633798B1 (en) * 1992-03-31 2003-05-07 Boston Scientific Corporation Vascular filter
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
JP2746755B2 (en) 1993-01-19 1998-05-06 シュナイダー(ユーエスエー)インク Clad composite stent
US5824048A (en) 1993-04-26 1998-10-20 Medtronic, Inc. Method for delivering a therapeutic substance to a body lumen
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5326381A (en) * 1993-05-10 1994-07-05 Engelhard Corporation Use of polytetrafluoroethylene resin particles to reduce the abrasion of abrasive pigments
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
WO1995010989A1 (en) * 1993-10-19 1995-04-27 Scimed Life Systems, Inc. Intravascular stent pump
US5476500A (en) 1993-12-20 1995-12-19 Ventritex, Inc. Endocardial lead system with defibrillation electrode fixation
US5788979A (en) 1994-07-22 1998-08-04 Inflow Dynamics Inc. Biodegradable coating with inhibitory properties for application to biocompatible materials
EP0765660A3 (en) * 1995-09-28 1998-09-23 Takeda Chemical Industries, Ltd. Microcapsules comprising 2-piperazinone-1-acetic acid compounds
US5576072A (en) * 1995-02-01 1996-11-19 Schneider (Usa), Inc. Process for producing slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with at least one other, dissimilar polymer hydrogel
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US5587507A (en) 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
JPH10506560A (en) * 1995-04-19 1998-06-30 シュナイダー(ユーエスエー)インク Coated stent releases the drug
CA2178541C (en) * 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
US5609629A (en) 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
EP0853465A4 (en) * 1995-09-01 1999-10-27 Univ Emory Endovascular support device and method of use
DE19539449A1 (en) 1995-10-24 1997-04-30 Biotronik Mess & Therapieg A process for preparing intraluminal stents of bioresorbable polymeric material
US5683447A (en) 1995-12-19 1997-11-04 Ventritex, Inc. Lead with septal defibrillation and pacing electrodes
US5658327A (en) 1995-12-19 1997-08-19 Ventritex, Inc. Intracardiac lead having a compliant fixation device
JPH09215753A (en) * 1996-02-08 1997-08-19 Schneider Usa Inc Self-expanding stent made of titanium alloy
EP0800801A1 (en) * 1996-04-10 1997-10-15 Advanced Cardiovascular Systems, Inc. Stent having varied amounts of structural strength along its length
US5830217A (en) * 1996-08-09 1998-11-03 Thomas J. Fogarty Soluble fixation device and method for stent delivery catheters
US5797887A (en) * 1996-08-27 1998-08-25 Novovasc Llc Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation
US6387121B1 (en) * 1996-10-21 2002-05-14 Inflow Dynamics Inc. Vascular and endoluminal stents with improved coatings
US6099561A (en) 1996-10-21 2000-08-08 Inflow Dynamics, Inc. Vascular and endoluminal stents with improved coatings
US5869141A (en) * 1996-11-04 1999-02-09 The Boeing Company Surface pretreatment for sol coating of metals
US5976178A (en) * 1996-11-07 1999-11-02 Vascular Science Inc. Medical grafting methods
US5833651A (en) * 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
DE69737208T2 (en) * 1996-11-15 2007-11-08 Cook Inc., Bloomington The stent delivery device having a separable case
US5871437A (en) 1996-12-10 1999-02-16 Inflow Dynamics, Inc. Radioactive stent for treating blood vessels to prevent restenosis
US5980972A (en) * 1996-12-20 1999-11-09 Schneider (Usa) Inc Method of applying drug-release coatings
US5830229A (en) * 1997-03-07 1998-11-03 Micro Therapeutics Inc. Hoop stent
US6200335B1 (en) * 1997-03-31 2001-03-13 Kabushikikaisha Igaki Iryo Sekkei Stent for vessel
US6240616B1 (en) * 1997-04-15 2001-06-05 Advanced Cardiovascular Systems, Inc. Method of manufacturing a medicated porous metal prosthesis
US5843172A (en) * 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
DE19724230C1 (en) 1997-04-30 1998-11-26 Schering Ag Applying radioactive coating to stent that has been treated with adhesion promoter
DE19731021A1 (en) * 1997-07-18 1999-01-21 Meyer Joerg In vivo degradable metallic implant
US6174330B1 (en) * 1997-08-01 2001-01-16 Schneider (Usa) Inc Bioabsorbable marker having radiopaque constituents
US5899935A (en) * 1997-08-04 1999-05-04 Schneider (Usa) Inc. Balloon expandable braided stent with restraint
DE19734972A1 (en) * 1997-08-13 1999-02-18 Cerdec Ag Gold-containing nanoporous alumina membranes, processes for their preparation and their use
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
EP1021232A1 (en) * 1997-09-08 2000-07-26 Cuno Incorporated End-cap for pleated filter cartridge
US6989435B2 (en) * 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7455853B2 (en) * 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US5972027A (en) * 1997-09-30 1999-10-26 Scimed Life Systems, Inc Porous stent drug delivery system
DE69842217D1 (en) 1997-11-07 2011-05-19 State University Radiopacity polymeric Biomateriale
US6151525A (en) * 1997-11-07 2000-11-21 Medtronic, Inc. Method and system for myocardial identifier repair
WO1999030772A3 (en) 1997-12-17 1999-10-21 Cardiac Pacemakers Inc Lead system
US6221425B1 (en) * 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US6541116B2 (en) * 1998-01-30 2003-04-01 Advanced Cardiovascular Systems, Inc. Superoxide dismutase or superoxide dismutase mimic coating for an intracorporeal medical device
US6488701B1 (en) * 1998-03-31 2002-12-03 Medtronic Ave, Inc. Stent-graft assembly with thin-walled graft component and method of manufacture
US5980566A (en) 1998-04-11 1999-11-09 Alt; Eckhard Vascular and endoluminal stents with iridium oxide coating
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
US7967855B2 (en) * 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US6206914B1 (en) * 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
JP2002517300A (en) 1998-06-10 2002-06-18 ジョージア テック リサーチ コーポレイション Microneedle device and a manufacturing method and use thereof
EP0966979B1 (en) 1998-06-25 2006-03-08 Biotronik AG Implantable bioresorbable support for the vascular walls, in particular coronary stent
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6212434B1 (en) * 1998-07-22 2001-04-03 Cardiac Pacemakers, Inc. Single pass lead system
US6755856B2 (en) * 1998-09-05 2004-06-29 Abbott Laboratories Vascular Enterprises Limited Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation
US6358276B1 (en) * 1998-09-30 2002-03-19 Impra, Inc. Fluid containing endoluminal stent
DE19948783C2 (en) 1999-02-18 2001-06-13 Alcove Surfaces Gmbh implant
DE19855421C2 (en) 1998-11-02 2001-09-20 Alcove Surfaces Gmbh implant
US6361780B1 (en) * 1998-11-12 2002-03-26 Cardiac Pacemakers, Inc. Microporous drug delivery system
US6099455A (en) * 1998-11-25 2000-08-08 Isostent, Inc. Radioisotope stent with non-radioactive end sections
DE60034317D1 (en) 1999-02-25 2007-05-24 Ge Healthcare Ltd Medical instruments and devices with improved ultrasound visibility
US6245104B1 (en) * 1999-02-28 2001-06-12 Inflow Dynamics Inc. Method of fabricating a biocompatible stent
US6214037B1 (en) * 1999-03-18 2001-04-10 Fossa Industries, Llc Radially expanding stent
US6331186B1 (en) * 1999-03-22 2001-12-18 Scimed Life Systems, Inc. End sleeve coating for stent delivery
US6258117B1 (en) * 1999-04-15 2001-07-10 Mayo Foundation For Medical Education And Research Multi-section stent
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
CA2368679C (en) 1999-05-01 2010-11-09 Qinetiq Limited Derivatized porous silicon
JP2001019401A (en) * 1999-07-05 2001-01-23 Seijiro Suda Hydrogen generating agent and hydrogen generating method utilizing the same
US7807211B2 (en) * 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
DE19950386A1 (en) * 1999-10-19 2001-05-10 Miladin Lazarov biocompatible subject
US6602287B1 (en) * 1999-12-08 2003-08-05 Advanced Cardiovascular Systems, Inc. Stent with anti-thrombogenic coating
US6251136B1 (en) * 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US7179849B2 (en) * 1999-12-15 2007-02-20 C. R. Bard, Inc. Antimicrobial compositions containing colloids of oligodynamic metals
US6338739B1 (en) * 1999-12-22 2002-01-15 Ethicon, Inc. Biodegradable stent
US8026263B2 (en) * 2000-01-06 2011-09-27 The Regents Of The University Of California Methods for inhibiting neoproliferative changes in blood vessel walls
US6534033B1 (en) * 2000-01-07 2003-03-18 Millennium Cell, Inc. System for hydrogen generation
US6290722B1 (en) * 2000-03-13 2001-09-18 Endovascular Technologies, Inc. Tacky attachment method of covered materials on stents
US8088060B2 (en) * 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US6451050B1 (en) * 2000-04-28 2002-09-17 Cardiovasc, Inc. Stent graft and method
US7247338B2 (en) * 2001-05-16 2007-07-24 Regents Of The University Of Minnesota Coating medical devices
US6395326B1 (en) * 2000-05-31 2002-05-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for depositing a coating onto a surface of a prosthesis
US6629992B2 (en) * 2000-08-04 2003-10-07 Advanced Cardiovascular Systems, Inc. Sheath for self-expanding stent
US6478815B1 (en) * 2000-09-18 2002-11-12 Inflow Dynamics Inc. Vascular and endoluminal stents
US6805898B1 (en) * 2000-09-28 2004-10-19 Advanced Cardiovascular Systems, Inc. Surface features of an implantable medical device
US6953560B1 (en) * 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6558733B1 (en) * 2000-10-26 2003-05-06 Advanced Cardiovascular Systems, Inc. Method for etching a micropatterned microdepot prosthesis
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
US20030033007A1 (en) * 2000-12-22 2003-02-13 Avantec Vascular Corporation Methods and devices for delivery of therapeutic capable agents with variable release profile
US7077859B2 (en) * 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US7083642B2 (en) * 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
US6663662B2 (en) * 2000-12-28 2003-12-16 Advanced Cardiovascular Systems, Inc. Diffusion barrier layer for implantable devices
GB0100760D0 (en) * 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US20020092583A1 (en) 2001-01-16 2002-07-18 Pelton Alan R. Medical devices, particularly stents, and methods for their manufacture
WO2002072167A1 (en) * 2001-03-13 2002-09-19 Implant Sciences Corporation. Drug eluting encapsulated stent
US6697662B2 (en) * 2001-03-23 2004-02-24 Alcover Surfaces Gmbh Surgical instrument
US6613077B2 (en) * 2001-03-27 2003-09-02 Scimed Life Systems, Inc. Stent with controlled expansion
US6764505B1 (en) * 2001-04-12 2004-07-20 Advanced Cardiovascular Systems, Inc. Variable surface area stent
US7862495B2 (en) * 2001-05-31 2011-01-04 Advanced Cardiovascular Systems, Inc. Radiation or drug delivery source with activity gradient to minimize edge effects
US6589286B1 (en) 2001-09-12 2003-07-08 Jason Litner Eustachian tube stent
US7989018B2 (en) * 2001-09-17 2011-08-02 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US20030158598A1 (en) * 2001-09-17 2003-08-21 Control Delivery Systems, Inc. System for sustained-release delivery of anti-inflammatory agents from a coated medical device
CA2918219A1 (en) * 2001-09-28 2003-03-28 Kazuwa Nakao Therapeutic agents for achondroplasia
WO2003028660A3 (en) * 2001-10-04 2004-04-22 Agata Exner Drug delivery devices and methods
DE10150995A1 (en) * 2001-10-08 2003-04-10 Biotronik Mess & Therapieg Implant e.g. a stent, comprises a decomposable substance which allows contact between the cell proliferation inhibitor and the stent surroundings only after a specified time
US20030088307A1 (en) * 2001-11-05 2003-05-08 Shulze John E. Potent coatings for stents
US7585516B2 (en) * 2001-11-12 2009-09-08 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices
US20030104028A1 (en) * 2001-11-29 2003-06-05 Hossainy Syed F.A. Rate limiting barriers for implantable devices and methods for fabrication thereof
US6752826B2 (en) * 2001-12-14 2004-06-22 Thoratec Corporation Layered stent-graft and methods of making the same
US6940580B2 (en) * 2002-01-09 2005-09-06 Novartis Ag Polymeric articles having a lubricious coating and method for making the same
US7060089B2 (en) * 2002-01-23 2006-06-13 Boston Scientific Scimed, Inc. Multi-layer stent
US6887270B2 (en) * 2002-02-08 2005-05-03 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US20030176884A1 (en) 2002-03-12 2003-09-18 Marwane Berrada Everted filter device
US20030181973A1 (en) * 2002-03-20 2003-09-25 Harvinder Sahota Reduced restenosis drug containing stents
WO2003094991A1 (en) 2002-05-09 2003-11-20 Hemoteq Gmbh Medical products comprising a haemocompatible coating, production and use thereof
DE10223310A1 (en) * 2002-05-24 2003-12-11 Biotronik Mess & Therapieg A process for coating of implants with a polysaccharide layer
US7097850B2 (en) * 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
US7396539B1 (en) * 2002-06-21 2008-07-08 Advanced Cardiovascular Systems, Inc. Stent coatings with engineered drug release rate
US20040002752A1 (en) * 2002-06-26 2004-01-01 Scimed Life Systems, Inc. Sacrificial anode stent system
US20040086569A1 (en) * 2002-08-13 2004-05-06 Medtronic, Inc. Active agent delivery systems, medical devices, and methods
US7951392B2 (en) * 2002-08-16 2011-05-31 Boston Scientific Scimed, Inc. Microarray drug delivery coatings
US20040054104A1 (en) * 2002-09-05 2004-03-18 Pacetti Stephen D. Coatings for drug delivery devices comprising modified poly(ethylene-co-vinyl alcohol)
US7112572B2 (en) * 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
US7438722B1 (en) * 2002-09-20 2008-10-21 Advanced Cardiovascular Systems, Inc. Method for treatment of restenosis
US7758636B2 (en) * 2002-09-20 2010-07-20 Innovational Holdings Llc Expandable medical device with openings for delivery of multiple beneficial agents
US6971813B2 (en) * 2002-09-27 2005-12-06 Labcoat, Ltd. Contact coating of prostheses
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
US20040088038A1 (en) * 2002-10-30 2004-05-06 Houdin Dehnad Porous metal for drug-loaded stents
US7169178B1 (en) * 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
US7144419B2 (en) * 2003-01-24 2006-12-05 Medtronic Vascular, Inc. Drug-polymer coated stent with blended phenoxy and styrenic block copolymers
US7311727B2 (en) * 2003-02-05 2007-12-25 Board Of Trustees Of The University Of Arkansas Encased stent
US20040167610A1 (en) * 2003-02-26 2004-08-26 Fleming James A. Locking stent
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
JP2006525328A (en) * 2003-05-05 2006-11-09 イーライ リリー アンド カンパニー A method of treatment of heart disease
US7488343B2 (en) * 2003-09-16 2009-02-10 Boston Scientific Scimed, Inc. Medical devices
EP1674094A4 (en) * 2003-10-15 2009-12-09 Nanoegg Res Lab Inc Composition containing retinoic acid nanoparticles coated with polyvalent metal inorganic salt
US8157855B2 (en) * 2003-12-05 2012-04-17 Boston Scientific Scimed, Inc. Detachable segment stent
US20040204756A1 (en) * 2004-02-11 2004-10-14 Diaz Stephen Hunter Absorbent article with improved liquid acquisition capacity
US20050187608A1 (en) * 2004-02-24 2005-08-25 O'hara Michael D. Radioprotective compound coating for medical devices
US7901451B2 (en) * 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
EP1817288A4 (en) * 2004-10-28 2009-08-26 Medicure Int Inc Dual antiplatelet/anticoagulant pyridoxine analogs
US20070173923A1 (en) * 2006-01-20 2007-07-26 Savage Douglas R Drug reservoir stent
US20070179599A1 (en) * 2006-01-31 2007-08-02 Icon Medical Corp. Vascular protective device
US8585753B2 (en) * 2006-03-04 2013-11-19 John James Scanlon Fibrillated biodegradable prosthesis
US20080234810A1 (en) * 2006-06-28 2008-09-25 Abbott Cardiovascular Systems Inc. Amorphous Glass-Coated Drug Delivery Medical Device
US7794776B1 (en) * 2006-06-29 2010-09-14 Abbott Cardiovascular Systems Inc. Modification of polymer stents with radiation
US20080058921A1 (en) * 2006-08-09 2008-03-06 Lindquist Jeffrey S Improved adhesion of a polymeric coating of a drug eluting stent
US7875069B2 (en) * 2006-09-21 2011-01-25 Boston Scientific Scimed, Inc. Stent with support element
US20080077218A1 (en) * 2006-09-25 2008-03-27 Boston Scientific Scimed, Inc. Injection of therapeutic into porous regions of a medical device
US20080097577A1 (en) * 2006-10-20 2008-04-24 Boston Scientific Scimed, Inc. Medical device hydrogen surface treatment by electrochemical reduction
US7981150B2 (en) * 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US8070797B2 (en) * 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
EP2247269B1 (en) * 2008-01-24 2011-08-24 Boston Scientific Scimed, Inc. Stent for delivering a therapeutic agent from a side surface of a stent strut
WO2010011515A3 (en) * 2008-07-23 2010-11-25 Boston Scientific Scimed, Inc. Medical devices having inorganic barrier coatings
US20100106242A1 (en) * 2008-10-23 2010-04-29 Abbott Cardiovascular Systems Inc. Stent and method for making a stent
US8653155B2 (en) * 2009-08-13 2014-02-18 Boston Scientific Scimed, Inc. Polymers having lipophilic hydrocarbon and biodegradable polymeric segments
US20110066227A1 (en) * 2009-09-17 2011-03-17 Boston Scientific Scimed, Inc. Stent with Dynamic Drug Reservoirs
US9414901B2 (en) * 2009-10-01 2016-08-16 Indiana University Research And Technology Corporation Drug-eluting stents for adenosine receptor modulation
US8398916B2 (en) * 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071305A (en) * 1996-11-25 2000-06-06 Alza Corporation Directional drug delivery stent and method of use
EP1260214A1 (en) * 1997-04-30 2002-11-27 Schneider (Usa) Inc., Drug-releasing coatings for medical devices
US6506437B1 (en) * 2000-10-17 2003-01-14 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device having depots formed in a surface thereof
WO2002047739A2 (en) * 2000-12-15 2002-06-20 Md3, Inc. Protective coating for stent
EP1273314A1 (en) * 2001-07-06 2003-01-08 Terumo Kabushiki Kaisha Stent
WO2003035131A1 (en) * 2001-09-27 2003-05-01 Advanced Cardiovascular Systems, Inc. A rate-reducing membrane for release of an agent

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8066763B2 (en) 1998-04-11 2011-11-29 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US8449901B2 (en) 2003-03-28 2013-05-28 Innovational Holdings, Llc Implantable medical device with beneficial agent concentration gradient
US8574615B2 (en) 2006-03-24 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US8353949B2 (en) 2006-09-14 2013-01-15 Boston Scientific Scimed, Inc. Medical devices with drug-eluting coating
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese

Also Published As

Publication number Publication date Type
US8137397B2 (en) 2012-03-20 grant
US20050192657A1 (en) 2005-09-01 application

Similar Documents

Publication Publication Date Title
US6752829B2 (en) Stent with channel(s) for containing and delivering a biologically active material and method for manufacturing the same
EP0875218B1 (en) Porous medicated stent
US20010013166A1 (en) Method of manufacturing a medicated porous metal prosthesis
US20060193888A1 (en) Methods for using medical devices having nanoporous layers
US5972027A (en) Porous stent drug delivery system
US20060259131A1 (en) Medical devices including metallic films and methods for making same
US6471980B2 (en) Intravascular delivery of mycophenolic acid
US20090118818A1 (en) Endoprosthesis with coating
US20030190406A1 (en) Implantable device having substances impregnated therein and a method of impregnating the same
US20080317827A1 (en) Methods and Devices for Delivering Therapeutic Agents to Target Vessels
US20090306765A1 (en) Bioerodible Endoprosthesis
US6712845B2 (en) Coating for a stent and a method of forming the same
US20050197689A1 (en) Medical devices including metallic films and methods for making same
US20040034337A1 (en) Microarray drug delivery coatings
US20080086198A1 (en) Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation
US20060198869A1 (en) Bioabsorable medical devices
US20090123517A1 (en) Medical devices for releasing therapeutic agent and methods of making the same
US20080071348A1 (en) Medical Devices
US20100042206A1 (en) Bioabsorbable coatings for medical devices
US20060224237A1 (en) Fragile structure protective coating
US20040172127A1 (en) Modular stent having polymer bridges at modular unit contact sites
US20040088038A1 (en) Porous metal for drug-loaded stents
US20080183278A1 (en) Implantable medical endoprostheses
US7482034B2 (en) Expandable mask stent coating method
US7435256B2 (en) Method and apparatus for controlled delivery of active substance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct app. not ent. europ. phase